S&P 500   3,300.64 (-1.68%)
DOW   27,542.10 (-1.29%)
QQQ   263.63 (-2.47%)
AAPL   106.40 (-3.57%)
MSFT   197.24 (-2.79%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,915.00 (-3.12%)
NVDA   480.59 (-3.60%)
TSLA   432.81 (+2.22%)
BABA   271.06 (-1.69%)
CGC   16.32 (-0.49%)
GE   6.92 (-1.84%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   29.02 (-0.17%)
F   7.26 (-0.27%)
ACB   6.50 (-5.66%)
GILD   64.20 (-1.29%)
NFLX   460.99 (-1.96%)
DIS   128.84 (-1.06%)
BAC   25.39 (+0.16%)
BA   163.00 (-2.70%)
S&P 500   3,300.64 (-1.68%)
DOW   27,542.10 (-1.29%)
QQQ   263.63 (-2.47%)
AAPL   106.40 (-3.57%)
MSFT   197.24 (-2.79%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,915.00 (-3.12%)
NVDA   480.59 (-3.60%)
TSLA   432.81 (+2.22%)
BABA   271.06 (-1.69%)
CGC   16.32 (-0.49%)
GE   6.92 (-1.84%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   29.02 (-0.17%)
F   7.26 (-0.27%)
ACB   6.50 (-5.66%)
GILD   64.20 (-1.29%)
NFLX   460.99 (-1.96%)
DIS   128.84 (-1.06%)
BAC   25.39 (+0.16%)
BA   163.00 (-2.70%)
S&P 500   3,300.64 (-1.68%)
DOW   27,542.10 (-1.29%)
QQQ   263.63 (-2.47%)
AAPL   106.40 (-3.57%)
MSFT   197.24 (-2.79%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,915.00 (-3.12%)
NVDA   480.59 (-3.60%)
TSLA   432.81 (+2.22%)
BABA   271.06 (-1.69%)
CGC   16.32 (-0.49%)
GE   6.92 (-1.84%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   29.02 (-0.17%)
F   7.26 (-0.27%)
ACB   6.50 (-5.66%)
GILD   64.20 (-1.29%)
NFLX   460.99 (-1.96%)
DIS   128.84 (-1.06%)
BAC   25.39 (+0.16%)
BA   163.00 (-2.70%)
S&P 500   3,300.64 (-1.68%)
DOW   27,542.10 (-1.29%)
QQQ   263.63 (-2.47%)
AAPL   106.40 (-3.57%)
MSFT   197.24 (-2.79%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,915.00 (-3.12%)
NVDA   480.59 (-3.60%)
TSLA   432.81 (+2.22%)
BABA   271.06 (-1.69%)
CGC   16.32 (-0.49%)
GE   6.92 (-1.84%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   29.02 (-0.17%)
F   7.26 (-0.27%)
ACB   6.50 (-5.66%)
GILD   64.20 (-1.29%)
NFLX   460.99 (-1.96%)
DIS   128.84 (-1.06%)
BAC   25.39 (+0.16%)
BA   163.00 (-2.70%)
Log in
ETR:MOR

MorphoSys Stock Forecast, Price & News

€114.95
+1.55 (+1.37 %)
(As of 09/17/2020 12:00 AM ET)
Add
Compare
Today's Range
€111.50
Now: €114.95▼
€115.85
50-Day Range
€101.70
MA: €107.62▼
€116.55
52-Week Range
€65.25
Now: €114.95▼
€146.30
Volume102,126 shs
Average Volume153,687 shs
Market Capitalization$3.76 billion
P/E Ratio35.01
Dividend YieldN/A
BetaN/A
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.
Read More
MorphoSys logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.00 out of 5 stars


Industry, Sector and Symbol

Stock Exchange ETR
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolETR:MOR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.morphosys.de
Phone+49-89-899270

Debt

Debt-to-Equity Ratio7.18
Current Ratio5.41
Quick Ratio5.23

Price-To-Earnings

Trailing P/E Ratio35.01
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$293.21 million
Price / Sales12.83
Cash Flow€27.43 per share
Price / Cash Flow4.19
Book Value€20.07 per share
Price / Book5.73

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees329
Outstanding Shares32,717,600
Market Cap$3.76 billion
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
€114.95
+1.55 (+1.37 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys (ETR:MOR) Frequently Asked Questions

How has MorphoSys' stock been impacted by Coronavirus?

MorphoSys' stock was trading at €91.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MOR stock has increased by 26.2% and is now trading at €114.95.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of MorphoSys?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for MorphoSys.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for MorphoSys.

What price target have analysts set for MOR?

8 equities research analysts have issued 12 month price objectives for MorphoSys' shares. Their forecasts range from €105.00 to €150.00. On average, they expect MorphoSys' share price to reach €123.13 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts' price targets for MorphoSys.

Who are some of MorphoSys' key competitors?

Some companies that are related to MorphoSys include Repare Therapeutics (BLI), Vir Biotechnology (VIR), BTG (BTG), Abcam (ABC), Genus (GNS), Kodiak Sciences (KOD), Cronos Group (CRON), Harmony Biosciences (HRMY), Trillium Therapeutics (TRIL), Viela Bio (VIE), NGM Biopharmaceuticals (NGM), Kymera Therapeutics (KYMR), Concordia International (CXR), PureTech Health (PRTC) and Oxford BioMedica (OXB).
View all competitors.

What other stocks do shareholders of MorphoSys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), Solaredge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT), Mercadolibre (MELI), Neurocrine Biosciences (NBIX), Nightstar Therapeutics (NITE) and NVIDIA (NVDA).

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
  • Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
  • Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
  • Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
  • Mr. Klaus De Wall, Head of Accounting & Tax

What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €114.95.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $3.76 billion and generates $293.21 million in revenue each year. MorphoSys employs 329 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.de.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.

This page was last updated on 9/18/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.